Compare OCG & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OCG | CVKD |
|---|---|---|
| Founded | 2018 | 2022 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.4M |
| IPO Year | 2019 | 2022 |
| Metric | OCG | CVKD |
|---|---|---|
| Price | $1.54 | $1.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 19.1K | ★ 103.3K |
| Earning Date | 11-03-2026 | 11-16-2026 |
| Dividend Yield | ★ 10.27% | N/A |
| EPS Growth | N/A | ★ 23.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.01 | $0.82 |
| 52 Week High | $19.29 | $12.50 |
| Indicator | OCG | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 43.07 | 66.44 |
| Support Level | $1.46 | $0.88 |
| Resistance Level | $1.93 | $2.23 |
| Average True Range (ATR) | 0.11 | 0.21 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 18.97 | 78.44 |
Oriental Culture Holding Ltd is an online provider of collectibles and artwork e-commerce services. The company also offers online and offline integrated marketing, storage, and technical maintenance services to customers. The company operates through one segment, namely, e-commerce of artwork trading. The company generates revenue through listing service fees, transaction fees, and other revenues collected from traders.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.